Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAVO: SC Daratumumab + rHuPH20 in RRMM
NCT02519452Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of daratumumab in multiple myeloma (MM) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Serum Trough Concentrations of Daratumumab and Adverse Events up to 3.4 years. Started Oct 2015; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02519452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519452.